BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical BenefitGlobeNewsWire • 12/06/23
BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic TumorGlobeNewsWire • 11/30/23
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ INDGlobeNewsWire • 11/03/23
BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology CandidateGlobeNewsWire • 10/25/23
October is Breast Cancer Awareness Month – BriaCell is Leading the Fight with its Innovative TechnologyGlobeNewsWire • 10/20/23
BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) ConferencesGlobeNewsWire • 10/18/23
BriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT™ Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo ClinicGlobeNewsWire • 10/11/23
BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT™ in Advanced Breast CancerGlobeNewsWire • 10/04/23
BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in Advanced Metastatic Breast CancerGlobeNewsWire • 10/03/23
BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast CancerGlobeNewsWire • 09/08/23
BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing ShareholdersGlobeNewsWire • 08/31/23
BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast CancerGlobeNewsWire • 08/31/23
BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) to Existing ShareholdersGlobeNewsWire • 08/25/23
BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS™ Immunotherapy for CancerGlobeNewsWire • 08/16/23
FDA Approves BriaCell's Pivotal Registrational Study Design in Advanced Metastatic Breast CancerGlobeNewsWire • 06/27/23
BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.GlobeNewsWire • 05/25/23
BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per ShareGlobeNewsWire • 05/19/23
BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.GlobeNewsWire • 05/15/23
BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACRGlobeNewsWire • 04/17/23
BriaCell Announces Intention to Spin-Out Certain Pre-Clinical Assets into a Newly Created “SpinCo” Entity whereby Shareholders to Receive One New Share of “SpinCo” in Addition to Each Current Share of BriaCell Already HeldGlobeNewsWire • 03/30/23
BriaCell to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual MeetingGlobeNewsWire • 03/15/23
BriaCell Therapeutics: Fast-Tracking High-Potential Breast Cancer ImmunotherapySeeking Alpha • 01/30/23